Ensuring access to HPV vaccines through integrated services: A reproductive health perspective

Bulletin of the World Health Organization

Volumn 85, Issue 1, 2007, Pages 57-63

  Pollack, Amy E ^a   Balkin, Miranda ^b   Edouard, Lindsay ^c   Cutts, Felicity ^d   Broutet, Nathalie ^d  

^a Mailman School of Public Health ^*  (United States)

^b Global Health Strategies   (United States)

^c UNITED NATIONS POPULATION FUND   (United States)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

CANCER; REPRODUCTIVE HEALTH; VACCINATION; VACCINE; VIRAL DISEASE;

CANCER PREVENTION; CANCER SCREENING; CONSUMER ADVOCACY; DRUG APPROVAL; HEALTH CARE POLICY; HEALTH PROGRAM; HEALTH SERVICE; HUMAN; IMMUNIZATION; IMMUNOGENICITY; MEDICAL INFORMATION; REPRODUCTIVE HEALTH; REVIEW; SEXUAL HEALTH; UTERINE CERVIX CANCER; VACCINATION; WART VIRUS;

FEMALE; HEALTH SERVICES ACCESSIBILITY; HUMANS; IMMUNIZATION PROGRAMS; MALE; PAPILLOMAVIRUS VACCINES; PRACTICE GUIDELINES; REPRODUCTIVE HEALTH SERVICES; UTERINE CERVICAL NEOPLASMS;

HUMAN PAPILLOMAVIRUS;

EID: 33846253652     PISSN: 00429686     EISSN: 15640604     Source Type: Journal    
DOI: 10.2471/BLT.06.034397     Document Type: Review

References (46)

1. Parikh S, Brennan P, Boffeta P. Meta-analysis of social inequality and the risk of cervical cancer. Int J Cancer 2003;105:687-91.
2. Reproductive health strategy to accelerate progress towards the attainment of international development goals and targets. Geneva: WHO; 2005.
3. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics 2002. CA Cancer J Clin 2005;55:74-108.
4. Projections of mortality and burden of disease to 2030, 2005. Available from: http://www.who.int/healthinfo/statistics/bodprojections2030/en/ index.html
5. Muñoz N, Bosch FX, Castellsague X, Diaz M, de Sanjose S, Hammouda D, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004;111:278-85.
6. Muñoz N, Mendez F, Posso H, Molano M, van den Brule AJ, Ronderos M, et al. Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J Infect Dis 2004;190:2077-87.
7. Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD, Gordillo-Tobar A, Levin C, Mahe C, et al. Cost effectiveness of cervical cancer screening in five developing countries. N Engl J Med 2005;353:2158-68.
8. Denny L, Kuhn L, de Souza M, Pollack AE, Dupree W, Wright TC. Screen-and-treat approaches for cervical cancer prevention in low-resource settings. JAMA 2005;294:2173-81.
9. Denny L. The prevention of cervical cancer in developing countries. BJOG 2005;112:1204-12.
10. Goldie SJ, Kuhn L, Denny L, Pollack AE, Wright TC. Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness. JAMA 2001;285:3107-15.
11. US Food and Drug Administration. Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine, 2006 (product approval information: licensing action). Available from: http://www.fda.gov/cber/ products/hpvmer060806.htm
12. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in young women: a randomized double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005;6:271-8.
13. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, et al. Sustained efficacy up to 4-5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006;367:1247-55.
14. Goldie SJ, Grima D, Kohli M, Wright TC, Weinstein M, Franco E. A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV 16/18 vaccine. Int J Cancer 2003;106:896-904.
15. Lowndes CM, Gill ON. Cervical cancer, human papillomavirus and vaccination. BMJ 2005;331:915-6.
16. Report of the Consultation on Human Papillomavirus Vaccines, 2005. Available from: http://www.who.int/entity/vaccine_research/documents/ 816%20%20HPV%20meeting.pdf
17. WHO consultation on human papillomavirus vaccines. Wkly Epidemiol Rec 2005;35:299-302.
18. Smith JF, Brownlow MK, Brown MJ, Esser MT, Ruiz W, Brown DR. Gardasil™ antibodies cross-neutralize pseudovirion infection of vaccine-related HPV types, 2006. Available from: http://www.abstracts2view. com/ipv/ (abstract no. PL 1-6).
19. Mahoney RT, Maynard JE. The introduction of new vaccines into developing countries. Vaccine 1999;17:646-52.
20. Sherris J, Agurto I, Arrossi S, Dzuba I, Gaffikin L, Herdman C. Advocating for cervical cancer prevention. Int J Gynecol Obstet 2005;89 Suppl 2:S46-54.
21. Kahn JA, Zimet GD, Bernstein DI, Riedesel JM, Lan D, Huang B, et al. Pediatrician's intention to administer human papillomavirus vaccine: the role of practice characteristics, knowledge and attitudes. J Adolesc Health 2005;37:502-10.
22. Zimet GD. Understanding and overcoming barriers to human Papillomavirus vaccine acceptance. Curr Opin Obstet Gynecol 2006:18 Suppl 11: S23-8.
23. Agurto I, Arrossi S, White S, Coffey P, Dzuba I, Bingham A, et al. Involving the community in cervical cancer prevention programs. Int J Gynecol Obstet 2005;89 Suppl 2:S38-45.
24. Mao C, Koutsky LA, Ault KA, Wheeler CM, Brown DR, Wiley DJ, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2006;107:18-27.
25. Villa LL, Ault KA, Giuliano AR, Costa RLR, Petta CA, Andrade RP, et al. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18. Vaccine 2006;24:5571-83.
26. Henry J. Kaiser Family Health Foundation. GSK HPV vaccine produces stronger immune response in girls ages 10 - 14 than in older women, 2005. Available from:. http://www.kaisernetwork.org/daily_reports/rep_index.cfm?hint= 2&DR_ID=34384
27. Soares C. Polio postponed: politics slow polio's eradication - and cause it to spread. Sci Am 2005;292:8-9.
28. Paavonen J, Halttunen M, Hansson BG, Nieminen P, Rostila T, Lehtinen M. Prerequisites for human papillomavirus vaccine trial: results of feasibility studies. J Clin Virol 2000;19:25-30.
29. Gudmundsdottir T, Tryggvadottir L, Allende M, Mast TC, Briem H, Sigurdsson K. Eligibility and willingness of young Icelandic women to participate in a HPV vaccination trial. Acta Obstet Gynecol Scand 2003;82:345-50.
30. Partridge JM, Koutsky LA. Genital human papillomavirus infection in men. Lancet Infect Dis 2006;6:21-31.
31. Barnabas RV, Laukkanen P, Koskela P, Kontula O, Lehtinen M, Garnett GP. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impacct of vaccination: mathematical modelling analyses. PLoS Med 2006;3:e138.
32. Villa LL. Prophylactic HPV vaccines: reducing the burden of HPV-related diseases. Vaccine 2006;24 Suppl 1:S23-8.
33. Chin-Hong PV, Vittinghoff E, Cranston RD, Browne L, Buchbinder S, Colfax G, et al. Age-related prevalence of anal cancer precursors in homosexual men: the EXPLORE study. J Natl Cancer Inst 2005;97:896-905.
34. Daling JR, Madeleine MM, Johnson LG, Schwartz SM, Shera KA, Wurscher MA, et al. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer 2004;101:270-80.
35. Bradley J, Barone M, Mahe C, Lewis R, Luciani S. Delivering cervical cancer prevention services in low-resource settings. Int J Gynecol Obstet 2005;89:S21-9.
36. Khalil MK, Al-Mazrou YY, AlHowasi MN, Al-Jeffri M. Measles in Saudi Arabia: from control to elimination. Ann Saudi Med 2005;25:324-8.
37. Tung CS, Middleman AB. An evaluation of school-level factors used in a successful school-based hepatitis B immunization initiative. J Adolesc Health 2005;37:61-8.
38. Wilson TR, Fishbein DB, Ellis PA, Edlavitch SA. The impact of a school entry law on adolescent immunization rates. J Adolesc Health 2005;37:511-6.
39. Wallace LA, Young D, Brown A, Cameron JC, Ahmed S, Duff R, et al. Costs of running a universal adolescent hepatitis B vaccination programme. Vaccine 2005;23:5624-31.
40. United Nations Educational, Scientific and Cultural Organization (UNESCO). Primary education: girls, 2006. Available from: http://portal.unesco.org/education/en/ev.php-URL_ID=30870&URL_DO= DO_TOPIC&URL_SECTION=201.html
41. Yameogo KR, Perry RT, Yameogo A, Kambire C, Konde MK, Nshimiriman D, et al. Migration as a risk factor for measles after a mass vaccination campaign, Burkina Faso, 2002. Int J Epidemiol 2005;34:556-64.
42. United Nations Population Fund (UNFPA). The world reaffirms Cairo: official outcomes of the ICPD at ten review, 2006. Available from: http://www.unfpa.org/publications/detail.cfm?ID=226
43. International Conference on Population and Development (ICPD). Summary of the ICPD programme of action. Chapter IV: gender equality, equity and empowerment of women, 1995. Available from: http://www.unfpa.org/icpd/ summary.htm#chapter4
44. Mathur S, Mehta M, Malhotra A. Youth reproductive health in Nepal: is participation the answer? 2004. Available from: http://www.engenderhealth. org/ia/foc/pdf/yrh-nepal.pdf
45. Bilous J, Eggers R, Gasse F, Jarrett S, Lydon P, Magan A, et al. A new global immunization vision and strategy. Lancet 2006;367:1464-6.
46. Churchwell C. Funding R&D for neglected diseases, 2005. Available from: http://hbswk.hbs.edu/item.jhtml?id=4665&t=globalization